Patents Assigned to MacroGenics, Inc.
-
Publication number: 20110243941Abstract: The present invention relates to molecules, particularly polypeptides, more particularly immunoglobulins (e.g., antibodies), comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region, which variant Fc region binds Fc?RIIIA and/or Fc?RIIA with a greater affinity, relative to a comparable molecule comprising the wild-type Fc region. The molecules of the invention are particularly useful in preventing, treating, or ameliorating one or more symptoms associated with a disease, disorder, or infection. The molecules of the invention are particularly useful for the treatment or prevention of a disease or disorder where an enhanced efficacy of effector cell function (e.g., ADCC) mediated by Fc?R is desired, e.g., cancer, infectious disease, and in enhancing the therapeutic efficacy of therapeutic antibodies the effect of which is mediated by ADCC.Type: ApplicationFiled: June 10, 2011Publication date: October 6, 2011Applicant: Macrogenics, Inc.Inventors: Jeffrey Stavenhagen, Sujata Vijh, Christopher Rankin, Sergey Gorlatov, Ling Huang
-
Patent number: 8003774Abstract: The present invention relates to molecules, particularly polypeptides, more particularly immunoglobulins (e.g., antibodies), comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region, which variant Fc region binds Fc?RIIIA and/or Fc?RIIA with a greater affinity, relative to a comparable molecule comprising the wild-type Fc region. The molecules of the invention are particularly useful in preventing, treating, or ameliorating one or more symptoms associated with a disease, disorder, or infection. The molecules of the invention are particularly useful for the treatment or prevention of a disease or disorder where an enhanced efficacy of effector cell function (e.g., ADCC) mediated by Fc?R is desired, e.g., cancer, infectious disease, and in enhancing the therapeutic efficacy of therapeutic antibodies the effect of which is mediated by ADCC.Type: GrantFiled: January 30, 2008Date of Patent: August 23, 2011Assignee: MacroGenics, Inc.Inventors: Jeffrey B. Stavenhagen, Sujata Vijh, Christopher Rankin, Sergey Gorlatov, Ling Huang
-
Publication number: 20110152504Abstract: CD 16A binding proteins useful for the reduction of a deleterious immune response asre described. In one aspect, humanized anti-cd16A antibodies, optionally lacking effector function, are used for the treatment of immune disorders such as idiopathic thrombocytopenic purpura and autoimme hemolytic anemia.Type: ApplicationFiled: October 14, 2010Publication date: June 23, 2011Applicant: MacroGenics, Inc.Inventors: Leslie S. Johnson, Ling Huang, Hua Li, Nadine Tuaillon
-
Patent number: 7960512Abstract: The present invention relates to molecules, particularly polypeptides, more particularly immunoglobulins (e.g., antibodies), comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region, which variant Fc region binds Fc?RIIIA and/or Fc?RIIA with a greater affinity, relative to a comparable molecule comprising the wild-type Fc region. The molecules of the invention are particularly useful in preventing, treating, or ameliorating one or more symptoms associated with a disease, disorder, or infection. The molecules of the invention are particularly useful for the treatment or prevention of a disease or disorder where an enhanced efficacy of effector cell function (e.g., ADCC) mediated by Fc?R is desired, e.g., cancer, infectious disease, and in enhancing the therapeutic efficacy of therapeutic antibodies the effect of which is mediated by ADCC.Type: GrantFiled: July 28, 2004Date of Patent: June 14, 2011Assignee: MacroGenics, Inc.Inventors: Jeffrey Stavenhagen, Sujata Vijh, Christopher Rankin, Sergey Gorlatov, Ling Huang
-
Publication number: 20110136689Abstract: The present invention provides a dual expression vector, and methods for its use, for the expression and secretion of a full-length polypeptide of interest in eukaryotic cells, and a soluble domain or fragment of the polypeptide in bacteria. When expressed in bacteria, transcription from a bacterial promoter within a first intron and termination at the stop codon in a second intron results in expression of a fragment of the polypeptide, e.g., a Fab fragment, whereas in mammalian cells, splicing removes the bacterial regulatory sequences located in the two introns and generates the mammalian signal sequence, allowing expression of the full-length polypeptide, e.g., IgG heavy or light chain polypeptide. The dual expression vector system of the invention can be used to select and screen for new monoclonal antibodies, as well as to optimize monoclonal antibodies for binding to antigenic molecules of interest.Type: ApplicationFiled: January 26, 2011Publication date: June 9, 2011Applicant: MacroGenics, Inc.Inventors: Leslie Sydnor Johnson, Ling Huang
-
Publication number: 20110117089Abstract: This invention relates to chimeric and humanized antibodies that specifically bind the BCR complex, and particularly chimeric and humanized antibodies to the BCR complex. The invention also relates to methods of using the antibodies and compositions comprising them in the diagnosis, prognosis and therapy of diseases such as cancer, autoimmune diseases, inflammatory disorders, and infectious disease.Type: ApplicationFiled: March 25, 2009Publication date: May 19, 2011Applicant: MACROGENICS, INC.Inventors: Leslie S. Johnson, Ling Huang
-
Publication number: 20110097323Abstract: This invention relates to antibodies that specifically bind HER2/neu, and particularly chimeric 4D5 antibodies to HER2/neu, which have reduced glycosylation as compared to known 4D5 antibodies. The invention also relates to methods of using the 4D5 antibodies and compositions comprising them in the diagnosis, prognosis and therapy of diseases such as cancer, autoimmune diseases, inflammatory disorders, and infectious disease.Type: ApplicationFiled: March 25, 2009Publication date: April 28, 2011Applicant: MACROGENICS, INC.Inventors: Leslie S. Johnson, Ling Huang, Nadine Tuaillon, Ezio Bonvini
-
Publication number: 20110081347Abstract: This invention relates to antibodies with altered binding to FcRn, and particularly antibodies having enhanced binding to FcRn and/or enhanced serum half-lives. The invention also relates to methods of using the antibodies and compositions comprising them in the diagnosis, prognosis and therapy of diseases such as cancer, autoimmune diseases, inflammatory disorders, and infectious disease.Type: ApplicationFiled: June 4, 2009Publication date: April 7, 2011Applicant: MacroGenics, Inc.Inventor: Sergey Gorlatov
-
Patent number: 7906327Abstract: The present invention provides a dual expression vector, and methods for its use, for the expression and secretion of a full-length polypeptide of interest in eukaryotic cells, and a soluble domain or fragment of the polypeptide in bacteria. When expressed in bacteria, transcription from a bacterial promoter within a first intron and termination at the stop codon in a second intron results in expression of a fragment of the polypeptide, e.g., a Fab fragment, whereas in mammalian cells, splicing removes the bacterial regulatory sequences located in the two introns and generates the mammalian signal sequence, allowing expression of the full-length polypeptide, e.g., IgG heavy or light chain polypeptide. The dual expression vector system of the invention can be used to select and screen for new monoclonal antibodies, as well as to optimize monoclonal antibodies for binding to antigenic molecules of interest.Type: GrantFiled: August 10, 2006Date of Patent: March 15, 2011Assignee: MacroGenics, inc.Inventors: Leslie Sydnor Johnson, Ling Huang
-
Publication number: 20100322924Abstract: The present invention relates to humanized Fc?RIIB antibodies, fragments, and variants thereof that bind human Fc?RIIB with a greater affinity than said antibody binds Fc?RIIA. The invention encompasses the use of the humanized antibodies of the invention for the treatment of any disease related to loss of balance of Fc receptor mediated signaling, such as cancer, autoimmune and inflammatory disease. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the humanized antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing the efficacy of a vaccine composition by administering the humanized antibodies of the invention. The invention encompasses methods for treating an autoimmune disease and methods for elimination of cancer cells that express Fc?RIIB.Type: ApplicationFiled: May 21, 2010Publication date: December 23, 2010Applicant: MacroGenics, Inc.Inventors: Leslie S. Johnson, Ling Huang
-
Publication number: 20100322851Abstract: The invention provides the identification and characterization of disease and cancer-associated epitope, KID3. The invention also provides a family of monoclonal antibodies that bind to KID3, methods of diagnosing and treating various human cancers and diseases that express KID3.Type: ApplicationFiled: July 7, 2010Publication date: December 23, 2010Applicant: MacroGenics, Inc.Inventors: Tony W. Liang, Deryk T. Loo, Xiaolin Xu
-
Patent number: 7838635Abstract: CD16A binding proteins useful for the reduction of a deleterious immune response are described. In one aspect, humanized anti-cd16A antibodies, optionally lacking effector function, are used for the treatment of immune disorders such as idiopathic thrombocytopenic purpura and autoimmune hemolytic anemia.Type: GrantFiled: June 4, 2007Date of Patent: November 23, 2010Assignee: MacroGenics, Inc.Inventors: Leslie S. Johnson, Ling Huang, Hua Li, Nadine Tuaillon
-
Patent number: 7790855Abstract: The invention provides the identification and characterization of disease and cancer-associated epitope, KID3. The invention also provides a family of monoclonal antibodies that bind to KID3, methods of diagnosing and treating various human cancers and diseases that express KID3.Type: GrantFiled: September 17, 2004Date of Patent: September 7, 2010Assignee: MacroGenics, Inc.Inventors: Tony W. Liang, Deryk T. Loo, Xiaolin Xu
-
Patent number: 7786270Abstract: The present invention relates to humanized Fc?RIIB antibodies, fragments, and variants thereof that bind human Fc?RIIB with a greater affinity than said antibody binds Fc?RIIA. The invention encompasses the use of the humanized antibodies of the invention for the treatment of any disease related to loss of balance of Fc receptor mediated signaling, such as cancer, autoimmune and inflammatory disease. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the humanized antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing the efficacy of a vaccine composition by administering the humanized antibodies of the invention. The invention encompasses methods for treating an autoimmune disease and methods for elimination of cancer cells that express Fc?RIIB.Type: GrantFiled: May 25, 2007Date of Patent: August 31, 2010Assignee: MacroGenics, Inc.Inventors: Leslie S. Johnson, Ling Huang
-
Patent number: 7776328Abstract: Provided herein is disclosure about the development and characterization of an antibody that binds to antigen EphA2 which is present on a variety of human cancers from breast, lung, prostate, and colons. Methods of diagnosing and treating various cancers by using such antibodies directed against this antigen are also disclosed.Type: GrantFiled: June 30, 2009Date of Patent: August 17, 2010Assignee: MacroGenics, Inc.Inventors: Jennie P. Mather, Penelope E. Roberts
-
Publication number: 20100196372Abstract: The present invention relates to molecules, preferably soluble (i.e., not membrane bound) polypeptides, most preferably soluble fusion polypeptides comprising the extracellular soluble regions of an Fc?R, derivatives and analogs thereof, and nucleic acids encoding same. Molecules of the invention are particularly useful for the treatment, management, or prevention of, or amelioration of one or more symptoms of, an autoimmune disease, especially for ameliorating serum platelet deficiency associated with immune thrombocytopenic purpura. The invention provides methods and compositions for enhancing the therapeutic efficacy of standard, current or experimental therapies for an autoimmune disease by administering a molecule of the invention.Type: ApplicationFiled: March 11, 2010Publication date: August 5, 2010Applicant: MacroGenics, Inc.Inventors: Leslie S. Johnson, Hua Li, Nadine Tuaillon
-
Publication number: 20100196362Abstract: The present invention relates to molecules having a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region. These modified molecules confer an effector function to a molecule, where the parent molecule does not detectably exhibit this effector function. In particular, the molecules of the invention have an increased effector cell function mediated by a Fc?R, such as, but not limited to, ADCC. In one embodiment, the variant Fc region binds Fc?RIIIA and/or Fc?RIIA with a greater affinity, relative to a comparable molecule comprising the wild-type Fc region.Type: ApplicationFiled: September 24, 2009Publication date: August 5, 2010Applicant: MACROGENICS, INC.Inventors: Jeffrey Stavenhagen, Scott Koenig
-
Publication number: 20100183605Abstract: The invention provides the identification and characterization of a disease and cancer-associated antigen, TES7. The invention also provides a family of monoclonal antibodies that bind to antigen TES7, methods of diagnosing and treating various human cancers and diseases with TES7.Type: ApplicationFiled: March 16, 2010Publication date: July 22, 2010Applicant: MACROGENICS, INC.Inventors: Jennie P. Mather, Tony W. Liang
-
Publication number: 20100174053Abstract: The present invention is directed to diabody molecules and uses thereof in the treatment of a variety of diseases and disorders, including immunological disorders, infectious disease, intoxication and cancers. The diabody molecules of the invention comprise two polypeptide chains that associate to form at least two epitope binding sites, which may recognize the same or different epitopes on the same or differing antigens. Additionally, the antigens may be from the same or different molecules. The individual polypeptide chains of the diabody molecule may be covalently bound through non-peptide bond covalent bonds, such as, but not limited to, disulfide bonding of cysteine residues located within each polypeptide chain. In particular embodiments, the diabody molecules of the present invention further comprise an Fc region, which allows antibody-like functionality to engineered into the molecule.Type: ApplicationFiled: December 17, 2009Publication date: July 8, 2010Applicant: MACROGENICS, INC.Inventors: Leslie S. JOHNSON, Ling HUANG
-
Patent number: 7718774Abstract: The invention provides the identification and characterization of disease and cancer-associated antigen, TES7. The invention also provides a family of monoclonal antibodies that bind to antigen TES7, methods of diagnosing and treating various human cancers and diseases that express TES7.Type: GrantFiled: November 8, 2007Date of Patent: May 18, 2010Assignee: MacroGenics, Inc.Inventors: Jennie P. Mather, Tony W. Liang